VolitionRX (VNRX)

• Market cap: $49.9M
• 1 day: -5.22%
• 5 days: -10.62%
• 1 month: -14.02%
• 3 months: -27.50%
• 6 months: -35.22%
• Year to date: -31.76%
• 1 year: -46.26%
• 5 years: -87.61%
• 10 years: -87.54%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Employees: 85

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

7% more capital invested

Capital invested by funds: $11.2M [Q4 2024] → $12M (+$762K) [Q1 2025]

2.42% more ownership

Funds ownership: 19.48% [Q4 2024] → 21.89% (+2.42%) [Q1 2025]

11% less funds holding

Funds holding: 28 [Q4 2024] → 25 (-3) [Q1 2025]

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.50 482% upside
• Avg. target: $3.75 772% upside
• High target: $5 1,063% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 22% 1-year accuracy 89 / 402 met price target	1,063% upside $5	Buy Maintained	30 Apr 2025
HC Wainwright & Co. Yi Chen 34% 1-year accuracy 55 / 160 met price target	482% upside $2.50	Buy Reiterated	11 Apr 2025